PMV Pharmaceuticals, Inc. Stockholders Equity

Quick Answer

PMV Pharmaceuticals, Inc. reported Stockholders Equity of $104.71 million for fiscal year 2025.

PMV Pharmaceuticals, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $104.71M -40.5%
2024 $176.08M -22.0%
2023 $225.69M -8.3%
2022 $246.03M -20.3%
2021 $308.56M -14.1%
2020 $359.12M +609.6%
2019 -$70.47M -52.7%
2018 -$46.14M -55.2%
2017 -$29.73M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $121.00M -38.9% -13.9%
June 30, 2025 $140.60M -34.4% -12.2%
March 31, 2025 $160.11M -24.7% -9.1%
December 31, 2024 $176.08M -22.0% -11.0%
September 30, 2024 $197.91M -16.7% -7.7%
June 30, 2024 $214.32M -1.6% +0.8%
March 31, 2024 $212.68M -7.6% -5.8%
December 31, 2023 $225.69M -8.3% -5.0%
  • PMV Pharmaceuticals, Inc. showed a decrease of -40.5% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2017–2025 period, PMV Pharmaceuticals, Inc.’s stockholders equity has grown by 452.2% (from -$29.73 million to $104.71 million).
  • The most recent figure is from PMV Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 6, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment